Steve M Taylor1, Christian M Parobek, Rick M Fairhurst. 1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA. taylo115@email.unc.edu
Abstract
BACKGROUND: Haemoglobinopathies can reduce the risk of malaria syndromes. We aimed to quantify the relation between different haemoglobin mutations and malaria protection to strengthen the foundation for translational studies of malaria pathogenesis and immunity. METHODS: We systematically searched the Medline and Embase databases for studies that estimated the risk of malaria in patients with and without haemoglobinopathies up to Sept 9, 2011, and identified additional studies from reference lists. We included studies that enrolled mainly children or pregnant women and had the following outcomes: Plasmodium falciparum severe malaria, uncomplicated malaria, asymptomatic parasitaemia, or pregnancy-associated malaria, and Plasmodium vivax malaria. Two reviewers identified studies independently, assessed quality of the studies, and extracted data. We produced odds ratios (ORs; 95% CIs) for case-control studies and incidence rate ratios (IRRs; 95% CIs) for prospective studies. We did the meta-analysis with a random-effects model when equivalent outcomes were reported in more than one study. FINDINGS: Of 62 identified studies, 44 reported data for haemoglobin AS, 19 for haemoglobin AC and CC, and 18 for α-thalassaemia. Meta-analysis of case-control studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (OR 0·09, 95% CI 0·06-0·12), haemoglobin CC (0·27, 0·11-0·63), haemoglobin AC (0·83, 0·67-0·96), homozygous α-thalassaemia (0·63, 0·48-0·83), and heterozygous α-thalassaemia (0·83, 0·74-0·92). In meta-analysis of prospective trials only haemoglobin AS was consistently associated with protection from uncomplicated malaria (IRR 0·69, 95% CI 0·61-0·79); no haemoglobinopathies led to consistent protection from asymptomatic parasitaemia. Few clinical studies have investigated β-thalassaemia, haemoglobin E, P. vivax malaria, or pregnancy-associated malaria. INTERPRETATION: Haemoglobin AS, CC, and AC genotypes and homozygous and heterozygous α-thalassaemia provide significant protection from severe malaria syndromes, but these haemoglobinopathies differ substantially in the degree of protection provided and confer mild or no protection against uncomplicated malaria and asymptomatic parasitaemia. Through attenuation of severity of malaria, haemoglobinopathies could serve as a model for investigation of the mechanisms of malaria pathogenesis and immunity. FUNDING: US National Institute of Allergy and Infectious Diseases.
BACKGROUND: Haemoglobinopathies can reduce the risk of malaria syndromes. We aimed to quantify the relation between different haemoglobin mutations and malaria protection to strengthen the foundation for translational studies of malaria pathogenesis and immunity. METHODS: We systematically searched the Medline and Embase databases for studies that estimated the risk of malaria in patients with and without haemoglobinopathies up to Sept 9, 2011, and identified additional studies from reference lists. We included studies that enrolled mainly children or pregnant women and had the following outcomes: Plasmodium falciparum severe malaria, uncomplicated malaria, asymptomatic parasitaemia, or pregnancy-associated malaria, and Plasmodium vivaxmalaria. Two reviewers identified studies independently, assessed quality of the studies, and extracted data. We produced odds ratios (ORs; 95% CIs) for case-control studies and incidence rate ratios (IRRs; 95% CIs) for prospective studies. We did the meta-analysis with a random-effects model when equivalent outcomes were reported in more than one study. FINDINGS: Of 62 identified studies, 44 reported data for haemoglobin AS, 19 for haemoglobin AC and CC, and 18 for α-thalassaemia. Meta-analysis of case-control studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (OR 0·09, 95% CI 0·06-0·12), haemoglobin CC (0·27, 0·11-0·63), haemoglobin AC (0·83, 0·67-0·96), homozygous α-thalassaemia (0·63, 0·48-0·83), and heterozygous α-thalassaemia (0·83, 0·74-0·92). In meta-analysis of prospective trials only haemoglobin AS was consistently associated with protection from uncomplicated malaria (IRR 0·69, 95% CI 0·61-0·79); no haemoglobinopathies led to consistent protection from asymptomatic parasitaemia. Few clinical studies have investigated β-thalassaemia, haemoglobin E, P. vivaxmalaria, or pregnancy-associated malaria. INTERPRETATION: Haemoglobin AS, CC, and AC genotypes and homozygous and heterozygous α-thalassaemia provide significant protection from severe malaria syndromes, but these haemoglobinopathies differ substantially in the degree of protection provided and confer mild or no protection against uncomplicated malaria and asymptomatic parasitaemia. Through attenuation of severity of malaria, haemoglobinopathies could serve as a model for investigation of the mechanisms of malaria pathogenesis and immunity. FUNDING: US National Institute of Allergy and Infectious Diseases.
Authors: Michael Aidoo; Dianne J Terlouw; Margarette S Kolczak; Peter D McElroy; Feiko O ter Kuile; Simon Kariuki; Bernard L Nahlen; Altaf A Lal; Venkatachalam Udhayakumar Journal: Lancet Date: 2002-04-13 Impact factor: 79.321
Authors: Marek Cyrklaff; Cecilia P Sanchez; Nicole Kilian; Cyrille Bisseye; Jacques Simpore; Friedrich Frischknecht; Michael Lanzer Journal: Science Date: 2011-11-10 Impact factor: 47.728
Authors: D Modiano; G Luoni; B S Sirima; J Simporé; F Verra; A Konaté; E Rastrelli; A Olivieri; C Calissano; G M Paganotti; L D'Urbano; I Sanou; A Sawadogo; G Modiano; M Coluzzi Journal: Nature Date: 2001-11-15 Impact factor: 49.962
Authors: Benno Kreuels; Christina Kreuzberg; Robin Kobbe; Matilda Ayim-Akonor; Peter Apiah-Thompson; Benedicta Thompson; Christa Ehmen; Samuel Adjei; Iris Langefeld; Ohene Adjei; Jürgen May Journal: Blood Date: 2010-03-15 Impact factor: 22.113
Authors: Ana Ferreira; Ivo Marguti; Ingo Bechmann; Viktória Jeney; Angelo Chora; Nuno R Palha; Sofia Rebelo; Annie Henri; Yves Beuzard; Miguel P Soares Journal: Cell Date: 2011-04-29 Impact factor: 41.582
Authors: Tamara D Clark; Bryan Greenhouse; Denise Njama-Meya; Bridget Nzarubara; Catherine Maiteki-Sebuguzi; Sarah G Staedke; Edmund Seto; Moses R Kamya; Philip J Rosenthal; Grant Dorsey Journal: J Infect Dis Date: 2008-08-01 Impact factor: 5.226
Authors: Thomas N Williams; Tabitha W Mwangi; David J Roberts; Neal D Alexander; David J Weatherall; Sammy Wambua; Moses Kortok; Robert W Snow; Kevin Marsh Journal: PLoS Med Date: 2005-05-31 Impact factor: 11.069
Authors: Muminatou Jallow; Yik Ying Teo; Kerrin S Small; Kirk A Rockett; Panos Deloukas; Taane G Clark; Katja Kivinen; Kalifa A Bojang; David J Conway; Margaret Pinder; Giorgio Sirugo; Fatou Sisay-Joof; Stanley Usen; Sarah Auburn; Suzannah J Bumpstead; Susana Campino; Alison Coffey; Andrew Dunham; Andrew E Fry; Angela Green; Rhian Gwilliam; Sarah E Hunt; Michael Inouye; Anna E Jeffreys; Alieu Mendy; Aarno Palotie; Simon Potter; Jiannis Ragoussis; Jane Rogers; Kate Rowlands; Elilan Somaskantharajah; Pamela Whittaker; Claire Widden; Peter Donnelly; Bryan Howie; Jonathan Marchini; Andrew Morris; Miguel SanJoaquin; Eric Akum Achidi; Tsiri Agbenyega; Angela Allen; Olukemi Amodu; Patrick Corran; Abdoulaye Djimde; Amagana Dolo; Ogobara K Doumbo; Chris Drakeley; Sarah Dunstan; Jennifer Evans; Jeremy Farrar; Deepika Fernando; Tran Tinh Hien; Rolf D Horstmann; Muntaser Ibrahim; Nadira Karunaweera; Gilbert Kokwaro; Kwadwo A Koram; Martha Lemnge; Julie Makani; Kevin Marsh; Pascal Michon; David Modiano; Malcolm E Molyneux; Ivo Mueller; Michael Parker; Norbert Peshu; Christopher V Plowe; Odile Puijalon; John Reeder; Hugh Reyburn; Eleanor M Riley; Anavaj Sakuntabhai; Pratap Singhasivanon; Sodiomon Sirima; Adama Tall; Terrie E Taylor; Mahamadou Thera; Marita Troye-Blomberg; Thomas N Williams; Michael Wilson; Dominic P Kwiatkowski Journal: Nat Genet Date: 2009-05-24 Impact factor: 38.330
Authors: Kendra A Byrd; Thomas N Williams; Audrie Lin; Amy J Pickering; Benjamin F Arnold; Charles D Arnold; Marion Kiprotich; Holly N Dentz; Sammy M Njenga; Gouthami Rao; John M Colford; Clair Null; Christine P Stewart Journal: J Nutr Date: 2018-12-01 Impact factor: 4.798
Authors: Tatiana M Lopera-Mesa; Saibou Doumbia; Drissa Konaté; Jennifer M Anderson; Mory Doumbouya; Abdoul S Keita; Seidina A S Diakité; Karim Traoré; Michael A Krause; Ababacar Diouf; Samuel E Moretz; Gregory S Tullo; Kazutoyo Miura; Wenjuan Gu; Michael P Fay; Steve M Taylor; Carole A Long; Mahamadou Diakité; Rick M Fairhurst Journal: Lancet Haematol Date: 2015-03-24 Impact factor: 18.959
Authors: Svetlana Glushakova; Amanda Balaban; Philip G McQueen; Rosane Coutinho; Jeffery L Miller; Ralph Nossal; Rick M Fairhurst; Joshua Zimmerberg Journal: J Infect Dis Date: 2014-03-31 Impact factor: 5.226
Authors: Peter D Crompton; Jacqueline Moebius; Silvia Portugal; Michael Waisberg; Geoffrey Hart; Lindsey S Garver; Louis H Miller; Carolina Barillas-Mury; Susan K Pierce Journal: Annu Rev Immunol Date: 2014 Impact factor: 28.527
Authors: Thiago Castro-Gomes; Luiza C Mourão; Gisely C Melo; Wuelton M Monteiro; Marcus V G Lacerda; Érika M Braga Journal: Infect Immun Date: 2014-08-04 Impact factor: 3.441